or Try an Advanced Search...

    Technical Analysis for INSM - Insmed, Inc.

    Grade Last Price % Change Price Change
    B 55.05 -3.39% -1.93
    INSM closed down 3.39 percent on Friday, May 31, 2024, on 2.33 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical INSM trend table...
    Date Alert Name Type % Chg
    Slingshot Bullish Bullish Swing Setup 0.00%
    Parabolic Rise Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    New 52 Week Closing High Bullish -3.39%
    Pocket Pivot Bullish Swing Setup -3.39%
    Volume Surge Other -3.39%
    New 52 Week High Strength -3.39%
    Older End-of-Day Signals for INSM ...

       Recent Intraday Alerts

    Alert Time
    2x Volume Pace 1 day ago
    Down 5% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 3% 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    INSM Chart by TradingView
    Basic chart:

    Profile

    Insmed, Inc. Description

    Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Infectious Diseases Cystic Fibrosis Microbiology Bacterial Disease Pseudomonas Tuberculosis Bacteriology Lung Diseases Lung Infection Nontuberculous Mycobacteria Lung Infections Mycobacterium

    Is INSM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 Insmed to Host Commercial Webinar on June 4, 2024
    May 30 Insmed announces pricing of $650M public offering
    May 30 Insmed Announces Pricing of $650 Million Public Offering of Common Stock
    May 29 Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
    May 29 Insmed PT Raised to $67 at TD Cowen
    May 29 Insmed stocks soar as Phase III lung disease drug exceeds expectations
    May 29 Insmed intends to raise $500M via equity offering
    May 28 Insmed Announces Proposed $500 Million Public Offering of Common Stock
    May 28 Insmed stock blasts off over lung condition study results
    May 28 Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
    See more INSM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 58.82
    52 Week Low 18.78
    Average Volume 3,084,612
    200-Day Moving Average 26.85
    50-Day Moving Average 28.14
    20-Day Moving Average 30.77
    10-Day Moving Average 35.82
    Average True Range 3.58
    RSI (14) 83.53
    ADX 32.86
    +DI 61.58
    -DI 8.13
    Chandelier Exit (Long, 3 ATRs) 48.07
    Chandelier Exit (Short, 3 ATRs) 32.67
    Upper Bollinger Bands 53.69
    Lower Bollinger Band 7.86
    Percent B (%b) 1.03
    BandWidth 148.92
    MACD Line 6.11
    MACD Signal Line 2.38
    MACD Histogram 3.7319
    Fundamentals Value
    Market Cap 7.88 Billion
    Num Shares 143 Million
    EPS -5.29
    Price-to-Earnings (P/E) Ratio -10.41
    Price-to-Sales 14.32
    Price-to-Book 25.45
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 60.93
    Resistance 3 (R3) 61.13 59.37 59.95
    Resistance 2 (R2) 59.37 57.87 59.27 59.62
    Resistance 1 (R1) 57.21 56.95 56.33 57.01 59.30
    Pivot Point 55.45 55.45 55.01 55.35 55.45
    Support 1 (S1) 53.29 53.95 52.41 53.09 50.80
    Support 2 (S2) 51.53 53.03 51.43 50.48
    Support 3 (S3) 49.37 51.53 50.15
    Support 4 (S4) 49.17